DEFA14A: ZimVie Confirms Q2 Earnings Release and Pending $19.00 Per Share Acquisition by ARCHIMED

ZimVie Inc. announced its second quarter 2025 financial results will be reported on July 30, 2025, while reiterating its definitive agreement to be acquired by an ARCHIMED affiliate for $19.00 in cash per share, with the transaction expected to close by year-end 2025.

Summary

• ZimVie Inc. will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025.
• On July 21, 2025, ZimVie announced a definitive agreement for its acquisition by an affiliate of ARCHIMED for $19.00 in cash per share.
• The acquisition transaction is expected to close by year-end 2025, subject to customary closing conditions, including stockholder and regulatory approvals.
• Upon completion of the transaction, ZimVie will become a privately held company, and its common stock will no longer be listed or publicly traded on NASDAQ.
• Due to the pending transaction, ZimVie will not host a conference call for the second quarter.
• ZimVie is withdrawing its fiscal 2025 guidance, and previous financial guidance should not be relied upon.

Sentiment

Score: 7

Explanation: The filing confirms a definitive acquisition agreement at a specific cash price, providing certainty for shareholders. While it signals the end of public trading and withdrawal of guidance, the acquisition itself is a positive event for current shareholders at the agreed price, assuming it closes. The risks listed are standard for M&A.

Positives

• A definitive agreement for acquisition provides certainty regarding the future of the company and a clear exit strategy for current shareholders.
• The acquisition price of $19.00 in cash per share offers a specific, fixed value for shareholders.
• The transaction is expected to close relatively soon, by year-end 2025, indicating a potentially swift realization of value for shareholders.

Negatives

• The withdrawal of fiscal 2025 guidance removes forward-looking financial transparency for public investors.
• The cancellation of the second quarter conference call limits immediate opportunities for investors to engage with management and gain further insights.
• Upon completion, ZimVie shares will no longer be publicly traded on NASDAQ, removing liquidity for existing shareholders.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Failure to receive required approval of the proposed transaction by ZimVie's stockholders.
• The possibility that any or all of the various other conditions to the consummation of the proposed transaction may not be satisfied or waived, including failure to receive any required regulatory approvals.
• The possibility that competing offers or acquisition proposals for ZimVie will be made.
• The occurrence of any event, change or other circumstance that could give rise to the termination of the definitive agreement, including circumstances which would require ZimVie to pay a termination fee.
• The effect of the pendency of the proposed transaction on ZimVie's ability to attract, motivate or retain key executives and employees.
• The effect of the pendency of the proposed transaction on ZimVie's ability to maintain relationships with its customers, suppliers and other business counterparties.
• The effect of the pendency of the proposed transaction on ZimVie's operating results and business generally.
• The risk that the proposed transaction will divert management's attention from ongoing business operations.
• The risk that ZimVie's stock price may decline significantly if the proposed transaction is not consummated.
• Dependence on new product development, technological advances and innovation.
• Shifts in the product category or regional sales mix of products and services.
• Supply and prices of raw materials and products, including impacts from tariffs.
• Pricing pressures from competitors, customers, dental practices and insurance providers.
• Changes in customer demand for products and services caused by demographic changes or other factors.
• Challenges relating to changes in and compliance with governmental laws and regulations affecting United States and international businesses.
• Competition.
• The impact of healthcare reform measures.
• Reductions in reimbursement levels by third-party payors.
• Cost containment efforts sponsored by government agencies, legislative bodies, the private sector and healthcare group purchasing organizations.
• Dependence on a limited number of suppliers for key raw materials and outsourced activities.
• The ability to obtain and maintain adequate intellectual property protection.
• Breaches or failures of information technology systems or products, including by cyberattack, unauthorized access or theft.
• The ability to retain the independent agents and distributors who market products.
• The ability to attract, retain and develop the highly skilled employees needed to support the business.
• The effect of mergers and acquisitions on relationships with customers, suppliers and lenders and on operating results and businesses generally.
• A determination by the Internal Revenue Service that the distribution of shares of common stock by Zimmer Biomet Holdings, Inc. in 2022 or certain related transactions should be treated as taxable transactions.
• The ability to form and implement alliances.
• Changes in tax obligations arising from tax reform measures, including European Union rules on state aid, or examinations by tax authorities.
• Product liability, intellectual property and commercial litigation losses.
• Changes in general industry and market conditions, including domestic and international growth rates.
• Changes in general domestic and international economic conditions, including inflation and interest rate and currency exchange rate fluctuations.
• The effects of global pandemics and other adverse public health developments on the global economy, business and operations and the business and operations of suppliers and customers.
• The impact of the ongoing financial and political uncertainty on countries in the Euro zone on the ability to collect accounts receivable in affected countries.

Future Outlook

The primary future outlook is the expected acquisition of ZimVie by an ARCHIMED affiliate for $19.00 per share in cash, anticipated to close by year-end 2025, subject to stockholder and regulatory approvals. Upon completion, ZimVie will become a privately held company and its shares will no longer be publicly traded. Fiscal 2025 guidance has been withdrawn.

Industry Context

The announcement signifies a consolidation within the dental implant market, with a publicly traded company transitioning to private ownership under a private equity firm. This reflects ongoing merger and acquisition activity in the life sciences and medical device sectors, particularly for specialized segments like dental solutions, where private equity firms identify value in established market leaders.

Stakeholder Impact

• Shareholders will receive $19.00 in cash per share upon completion of the acquisition, but shares will no longer be publicly traded.
• Employees and executives may be impacted by the pendency of the transaction, which could affect the company's ability to attract, motivate, or retain key personnel.
• Customers and suppliers may experience impacts from the pendency of the transaction, which could affect the company's ability to maintain existing business relationships.

Next Steps

• ZimVie to report Q2 2025 financial results and file Form 10-Q on July 30, 2025.
• ZimVie stockholders to vote on and approve the proposed transaction.
• Receipt of applicable regulatory approvals for the acquisition.
• ZimVie to file relevant materials with the SEC, including a proxy statement for the proposed transaction.
• Completion of the acquisition transaction by year-end 2025.

Key Dates

Recommendation

The definitive agreement for acquisition at $19.00 per share provides a clear target price. Given the transaction is expected to close by year-end 2025, holding shares until completion allows investors to realize the acquisition price, assuming the deal closes. There is limited upside beyond the offer price, and potential downside if the deal falls through, but the definitive agreement makes the 'hold' position reasonable for those seeking to capture the acquisition premium.

Keywords

Dental Implants, Life Sciences, Acquisition, Merger, ARCHIMED, ZimVie, ZIMV, NASDAQ Delisting, Private Equity, Healthcare, Medical Devices, Dental Solutions, Biomaterials, Digital Workflow